References
- Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6(2):148-58; PMID:16491139; http://dx.doi.org/10.1038/nri1777
- Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464(7286):217-23; PMID:20220840
- Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11: S45-53; PMID:15812489; http://dx.doi.org/10.1038/nm1213
- McGhee JR, Kiyono H. New perspectives in vaccine development: mucosal immunity to infections. Infect Agents Dis 1993; 2(2):55-73; PMID:8162356
- Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, Pallansch MA. Circulating vaccine-derived Polioviruses: current state of knowledge. Bull World Health Organ 2004; 82(1):16-23; PMID:15106296
- Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991; 163(1):1-6; PMID:1845806; http://dx.doi.org/10.1093/infdis/163.1.1
- Baqar S, Bourgeois AL, Schultheiss PJ, Walker RI, Rollins DM, Haberberger RL, Pavlovskis OR. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine 1995; 13(1): 22-8; PMID:7539199; http://dx.doi.org/10.1016/0264-410X(95)80006-Y
- McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono, H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992; 10(2):75-88; PMID:1539467; http://dx.doi.org/10.1016/0264-410X(92)90021-B
- Ryan EJ, Daly LM, Mills KH. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 2001; 19(8):293-304; PMID:11451471; http://dx.doi.org/10.1016/S0167-7799(01)01670-5
- Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82(5): 488-96; PMID:15479434; http://dx.doi.org/10.1111/j.0818-9641.2004.01272.x
- Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Zangwill K. The efficacy of live attenuated, cold-adapted, trivalent, intranasal Influenzavirus vaccine in children. N Engl J Med 1998; 338(20):1405-12; PMID:9580647; http://dx.doi.org/10.1056/NEJM199805143382002
- Van dr Lubben I, Verhoef J, Borchard G, Junginger H. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001; 52(2):139-44; PMID:11718937; http://dx.doi.org/10.1016/S0169-409X(01)00197-1
- Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against Influenza A virus infection in mice. Vaccine 2003; 21(23):3212-8; PMID:12804850; http://dx.doi.org/10.1016/S0264-410X(03)00234-2
- Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, Roden RB. Protection against heterologous Human Papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci 2008; 105(15):5850-5; PMID:18413606; http://dx.doi.org/10.1073/pnas.0800868105
- Lawson LB, Norton EB, Clements JD. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 2011; 23(3):414-20; PMID:21511452; http://dx.doi.org/10.1016/j.coi.2011.03.009
- Caputo A, Sparnacci K, Ensoli B, Tondelli, L. Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines. Curr Drug Deliv 2008; 5(4):230-42; PMID:18855591; http://dx.doi.org/10.2174/156720108785914961
- Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999; 17(11):1075-81; PMID:10545912; http://dx.doi.org/10.1038/15058
- Aguilar J, Rodriguez E. Vaccine adjuvants revisited. Vaccine 2007; 25(19):3752-62; PMID:17336431; http://dx.doi.org/10.1016/j.vaccine.2007.01.111
- Garg NK, Mangal S, Khambete H, Tyagi RK. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul 2010; 4(2):114-28; PMID:20380624; http://dx.doi.org/10.2174/187221110791185015
- O'Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev 1998; 34(2):305-20; PMID:10837683; http://dx.doi.org/10.1016/S0169-409X(98)00045-3